Literature DB >> 25404150

The EMT universe: space between cancer cell dissemination and metastasis initiation.

Luigi Ombrato1, Ilaria Malanchi1.   

Abstract

Tumor metastasis, the cause of more than 90% of cancer cell mortality, is a multistep process by which tumor cells disseminate from their primary site via local invasion and intravasation into blood or lymphatic vessels and reach secondary distant sites, where they survive and reinitiate tumor growth. Activation of a developmental program called the epithelial-to-mesenchymal transition (EMT) has been shown to be a very efficient strategy adopted by epithelial cancer cells to promote local invasion and dissemination at distant organs. Remarkably, the activation of EMT programs in epithelial cells correlates with the appearance of stemness. This finding suggests that the EMT process also drives the initial cancer cell colonization at distant sites. However, recent studies support the concept that its reverse program, a mesenchymal-to-epithelial transition, is required for efficient metastatic colonization and that EMT is not necessarily associated with stemness. This review analyzes the conflicting experimental evidence linking epithelial plasticity to stemness in the light of an "EMT gradient model," according to which the outcome of EMT program activation in epithelial cells would be bimodal: coupled to stemness during initial activation, but when forced to reach an advanced mesenchymal status, it would become incompatible with stem cell abilities.

Entities:  

Mesh:

Year:  2014        PMID: 25404150     DOI: 10.1615/critrevoncog.2014011802

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  72 in total

1.  Towards elucidating the connection between epithelial-mesenchymal transitions and stemness.

Authors:  Mohit Kumar Jolly; Bin Huang; Mingyang Lu; Sendurai A Mani; Herbert Levine; Eshel Ben-Jacob
Journal:  J R Soc Interface       Date:  2014-12-06       Impact factor: 4.118

Review 2.  The role of EMT and MET in cancer dissemination.

Authors:  Jacqueline Banyard; Diane R Bielenberg
Journal:  Connect Tissue Res       Date:  2015-08-20       Impact factor: 3.417

3.  Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric.

Authors:  Jason T George; Mohit Kumar Jolly; Shengnan Xu; Jason A Somarelli; Herbert Levine
Journal:  Cancer Res       Date:  2017-09-25       Impact factor: 12.701

Review 4.  Embryonic Chicken (Gallus gallus domesticus) as a Model of Cardiac Biology and Development.

Authors:  José G Vilches-Moure
Journal:  Comp Med       Date:  2019-06-10       Impact factor: 0.982

5.  EMT in cancer.

Authors:  Thomas Brabletz; Raghu Kalluri; M Angela Nieto; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2018-01-12       Impact factor: 60.716

6.  Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma.

Authors:  Hao Zhang; Qingqing Wang; Jun Liu; Haoqiang Cao
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

Review 7.  Cyclin A2: At the crossroads of cell cycle and cell invasion.

Authors:  Abdelhalim Loukil; Caroline T Cheung; Nawal Bendris; Bénédicte Lemmers; Marion Peter; Jean Marie Blanchard
Journal:  World J Biol Chem       Date:  2015-11-26

Review 8.  Multifunctional DDX3: dual roles in various cancer development and its related signaling pathways.

Authors:  Luqing Zhao; Yitao Mao; Jianhua Zhou; Yuelong Zhao; Ya Cao; Xiang Chen
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

Review 9.  Targeting tumor metastases: Drug delivery mechanisms and technologies.

Authors:  Vidya Ganapathy; Prabhas V Moghe; Charles M Roth
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

Review 10.  Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance.

Authors:  Plabon Kumar Das; Suja Pillai; Md Abdur Rakib; Jahan Ara Khanam; Vinod Gopalan; Alfred K Y Lam; Farhadul Islam
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.